{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:16Z","timestamp":1793406916413,"version":"4.5.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011539","name":"Masonic Cancer Center, University of Minnesota","doi-asserted-by":"publisher","award":["2017 CETI Translational Research Grant Award"],"award-info":[{"award-number":["2017 CETI Translational Research Grant Award"]}],"id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0357-3","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T10:53:18Z","timestamp":1529319198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-554X","authenticated-orcid":false,"given":"Evidio","family":"Domingo-Musibay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paari","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Giubellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"issue":"3","key":"357_CR1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/DAD.0b013e3181961861","volume":"31","author":"M Deprez","year":"2009","unstructured":"Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31(3):256\u201362.","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"357_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/archotol.1992.01880110113020","volume":"118","author":"JW Bailet","year":"1992","unstructured":"Bailet JW, et al. Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol Head Neck Surg. 1992;118(11):1245\u20139.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"357_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0190-9622(95)90001-2","volume":"33","author":"BR Nelson","year":"1995","unstructured":"Nelson BR, et al. Sebaceous carcinoma. J Am Acad Dermatol. 1995;33(1):1\u201315. quiz 16\u20138","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"357_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jaad.2016.07.046","volume":"75","author":"R Tripathi","year":"2016","unstructured":"Tripathi R, et al. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75(6):1210\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"357_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cncr.23952","volume":"115","author":"T Dasgupta","year":"2009","unstructured":"Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158\u201365.","journal-title":"Cancer"},{"issue":"1","key":"357_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000360806","volume":"6","author":"A Orcurto","year":"2014","unstructured":"Orcurto A, et al. Long-term remission of an aggressive sebaceous carcinoma following chemotherapy. Case Rep Dermatol. 2014;6(1):80\u20134.","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"357_CR7","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.3747\/co.22.2467","volume":"22","author":"V Kumar","year":"2015","unstructured":"Kumar V, Xu Y. Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours? Curr Oncol. 2015;22(4):e316\u20139.","journal-title":"Curr Oncol"},{"issue":"12","key":"357_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/bjophthalmol-2011-300612","volume":"95","author":"BJ Gaskin","year":"2011","unstructured":"Gaskin BJ, et al. The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome. Br J Ophthalmol. 2011;95(12):1686\u201390.","journal-title":"Br J Ophthalmol"},{"key":"357_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15180","volume":"8","author":"I Cortes-Ciriano","year":"2017","unstructured":"Cortes-Ciriano I, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.","journal-title":"Nat Commun"},{"issue":"10105","key":"357_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362.","journal-title":"Lancet"},{"issue":"26","key":"357_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"26","key":"357_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, et al. PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"10","key":"357_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"9","key":"357_CR14","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.humpath.2013.02.003","volume":"44","author":"C Boussahmain","year":"2013","unstructured":"Boussahmain C, Mochel MC, Hoang MP. Perilipin and adipophilin expression in sebaceous carcinoma and mimics. Hum Pathol. 2013;44(9):1811\u20136.","journal-title":"Hum Pathol"},{"issue":"1","key":"357_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajo.2013.08.015","volume":"157","author":"FA Jakobiec","year":"2014","unstructured":"Jakobiec FA, Mendoza PR. Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin. Am J Ophthalmol. 2014;157(1):186\u2013208. e2","journal-title":"Am J Ophthalmol"},{"issue":"D1","key":"357_CR16","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777\u201383.","journal-title":"Nucleic Acids Res"},{"key":"357_CR17","doi-asserted-by":"crossref","unstructured":"Long GV, et al. PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): a pooled analysis. Ann Oncol. 2016;27","DOI":"10.1093\/annonc\/mdw379.07"},{"key":"357_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","volume":"5","author":"EJ Lipson","year":"2017","unstructured":"Lipson EJ, et al. Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer. 2017;5:23.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"357_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","volume":"1","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54\u201363.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"357_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2217\/imt-2015-0002","volume":"8","author":"PN Aguiar Jr","year":"2016","unstructured":"Aguiar PN Jr, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8(4):479\u201388.","journal-title":"Immunotherapy"},{"key":"357_CR21","doi-asserted-by":"crossref","unstructured":"Khunger M, et al. Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1\/PD-L1 axis inhibitors in solid tumors. J Clin Oncol. 2016;34(15)","DOI":"10.1200\/JCO.2016.34.15_suppl.11603"},{"key":"357_CR22","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023\u201339.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"357_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrclinonc.2017.40","volume":"14","author":"CA Bradley","year":"2017","unstructured":"Bradley CA, et al. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol. 2017;14(9):562\u201376.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7408","key":"357_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500\u20134.","journal-title":"Nature"},{"key":"357_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/1471-2407-10-556","volume":"10","author":"WH Tu","year":"2010","unstructured":"Tu WH, et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 2010;10:556.","journal-title":"BMC Cancer"},{"issue":"1","key":"357_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-017-0836-3","volume":"19","author":"SK Chia","year":"2017","unstructured":"Chia SK, et al. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Res. 2017;19(1):54.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"357_CR27","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","volume":"16","author":"JP Eder","year":"2010","unstructured":"Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507\u201316.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"357_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/1389450116666141205160924","volume":"15","author":"LG Leon","year":"2014","unstructured":"Leon LG, et al. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 2014;15(14):1331\u201340.","journal-title":"Curr Drug Targets"},{"issue":"19","key":"357_CR29","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","volume":"17","author":"C Lieu","year":"2011","unstructured":"Lieu C, et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"357_CR30","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/1078-0432.CCR-09-2436","volume":"16","author":"MH Langenberg","year":"2010","unstructured":"Langenberg MH, et al. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2010;16(7):2187\u201397.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"357_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","volume":"28","author":"JD Miller","year":"2008","unstructured":"Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710\u201322.","journal-title":"Immunity"},{"issue":"3","key":"357_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, et al. PD-1 blockade expands Intratumoral memory T cells. Cancer Immunol Res. 2016;4(3):194\u2013203.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"357_CR33","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993\u20138.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0357-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0357-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T21:47:14Z","timestamp":1661464034000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0357-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0357-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"2 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patient described in this case signed a case report informed consent form which is available for review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consented to publication of the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"58"}}